You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. The Retroject Device: A Novel Approach to Glaucoma Drug Delivery

    SBC: RETROJECT, INC.            Topic: NEI

    PROJECT ABSTRACT Glaucoma is a common neurodegenerative disease which is the 2nd leading cause of blindness in the United States. With the aging baby boomer population, these numbers will continue to increase exponentially over the next few decades. With glaucomatous progression, there is ultimately damage to the optic nerve which results in peripheral vision loss. It has been shown in many prior ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Each year in the United States over 270,000 women will be diagnosed with breast cancer and over 40,000 will die from the disease. While multiple forms of breast cancer exist, a common theme in most of the forms involvesaberrations in signal transduction pathways that lead to inhibition of the programmed cell death process known as apoptosis. Apoptosis is a care ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. STTR Phase I: Novel Molecularly Targeted Tracer for Specific and Sensitive Imaging of Cancer

    SBC: CLAVE BIODESIGN, INC            Topic: EB

    This Small Business Technology Transfer Phase I project takes an innovative approach at tumor targeting by investigating an entirely novel tumor targeting platform that utilizes bone marrow derived, circulating tumor homing cells as natural vectors. Through screening of phage display peptide libraries we have identified high affinity peptide ligands that bind these cells with high specificity. The ...

    STTR Phase I 2013 National Science Foundation
  5. STTR Phase I: Metabolic engineering of photosynthesis for improved biomass accumulation

    SBC: Benson Hill Biosystems, Inc.            Topic: AS

    This Small Business Technology Transfer (STTR) Phase I project proposes to improve intrinsic crop yield through metabolic engineering of photosynthetic pathways. Genes encoding five rate-limiting enzymes for photosynthesis and starch synthesis will be co-expressed constitutively or in a cell-specific manner in a model C4 plant species. Multiple metabolic pathways will be altered to simultaneously ...

    STTR Phase I 2013 National Science Foundation
  6. STTR Phase II: Microgames for Improving Pediatric Compliance

    SBC: ARCHIE MD INC.            Topic: DG

    The innovation proposed in this Small Business Innovation Research Phase II project will harness the popularity and ubiquity of mobile microgames on hand-held devices for educating children on self-management of chronic health conditions. Millions of children suffer from chronic conditions which require regular management, such as diabetes, or from broader states of poor health caused by obesity. ...

    STTR Phase II 2013 National Science Foundation
  7. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic burden associated with primary and follow-up treatment costs, estimated at more than 40 billion dol ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Ultra-Flexible Hybrid Circuits for Intraocular Retinal Prostheses

    SBC: PREMITEC, INC.            Topic: N

    DESCRIPTION provided by applicant Retinal prosthetic devices currently under development are designed to bypass the non functioning portion of the visual pathway photoreceptor layer in individuals suffering from diseases including retinitis pigmentosa RP and age related macular degeneration AMD Current devices enable patients to only see object positions and read large letters and furth ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government